Navigation Links
Psychemedics Corporation Announces Top Revenue Quarter

ACTON, Mass., Aug. 5, 2013 /PRNewswire/ -- Psychemedics Corporation (NASDAQ: PMD) today announced second quarter financial results for the period ended June 30, 2013.  The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of August 15, 2013 to be paid on August 28, 2013.  This will be the Company's 68th consecutive quarterly dividend.

(Logo: )

The Company's revenue for the quarter ended June 30, 2013 was $6.90 million versus $6.86 million for the quarter ended June 30, 2012, an increase of 1%.  Net income for the quarter ended June 30, 2013 was $1.06 million or $0.20 per diluted share, versus $1.00 million or $0.19 per diluted share, for the comparable period last year, an increase of 6%. The Company's revenue for the six months ended June 30, 2013 was $13.33 million versus $13.11 million for the six months ended June 30, 2012, an increase of 2%. Net income for the six months ended June 30, 2013 was $1.89 million or $0.36 per diluted share, versus $1.83 million or $0.35 per diluted share, for the comparable period last year, an increase of 3%.

Raymond C. Kubacki, Chairman and Chief Executive Officer, said,

"We are very pleased to report record sales for this past quarter, which exceeds any quarter in the Company's history. Our new business growth is strong, while larger companies in our base business remain more cautious on hiring. In addition, the pre-tax margins were strong at 25%."We are also very excited about the launch of our hair alcohol test.  Alcohol is the most abused substance in the world, and excessive use poses serious health and safety risks.  After years of investing time and research into developing our hair alcohol test, we are proud to add this offering to our existing tests that measure consumption over an extended period of time.  (Please see our press release on July 8th, 2013, for further information on this exciting new product.) Last year we announced a new fundamental patent for getting the drugs out of the hair, and FDA clearance of new custom designed assays. We are very proud to continue to demonstrate our technological leadership with this new alcohol hair test.

"We continue to have a strong balance sheet with more than $2.7 million in cash and cash equivalents as of June 30, 2013 with no long term debt, despite heavy investment in new equipment and software over the last two years. 

"Our directors share our confidence in the long-term future of Psychemedics and remain committed to rewarding shareholders and sharing the financial success of the Company with them as we move forward. 

"Therefore, the Board has declared a $0.15 dividend for the quarter.  This is our 68th consecutive quarterly dividend."

Psychemedics Corporation is the world's largest provider of hair testing for the detection of drugs of abuse. The Company's patented process is used by thousands of U.S. and international clients, including over 10% of the Fortune 500 companies, for pre-employment and random drug testing. Major police departments, Federal Reserve Banks, schools, and other public entities also rely on our unique patented drug testing process. We strongly believe our drug testing method to be superior to any other product currently in use, including traditional urine testing and other hair testing methods.

The Psychemedics web site is

Cautionary Statement for purposes of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995:  From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties.  In particular, statements contained in this release that are not historical facts (including but not limited to statements concerning earnings, earnings per share, revenues, dividends, future business, growth opportunities, new accounts, customer base, market share, test volume and sales and marketing strategies) may be "forward looking" statements.  Actual results may differ from those stated in any forward-looking statements.  Factors that may cause such differences include but are not limited to risks associated with the development of markets for new products and services offered, government regulation, including but not limited to FDA regulations, competition and general economic conditions and other factors disclosed in the Company's filings with the Securities and Exchange Commission.Contact:

Neil LernerVice President of Finance(978)  Psychemedics CorporationStatements of Income and Comprehensive Income(UNAUDITED)Three Months EndedSix Months EndedJune 30,June 30,2013201220132012--Revenues

$6,898,737$6,861,720$13,331,179$13,105,575Cost of revenues

2,819,7882,758,3345,764,9595,337,069Gross profit

4,078,9494,103,3867,566,2207,768,506Operating Expenses:General & administrative

1,006,9501,004,5482,000,6611,999,989Marketing & selling

1,150,2441,220,7942,276,9022,345,619Research & development

190,036213,894354,746381,942Total Operating Expenses

2,347,2302,439,2364,632,3094,727,550Operating income

1,731,7191,664,1502,933,9113,040,956Other income

30048591,713995Net income before provision for income taxes

1,732,0191,664,6353,025,6243,041,951Provision for income taxes

669,093663,5911,140,3531,213,416Net income and comprehensive income

$1,062,926$1,001,044$1,885,271$1,828,535Basic net income per share

$0.20$0.19$0.36$0.35Diluted net income per share

$0.20$0.19$0.36$0.35Dividends declared per share

$0.15$0.15$0.30$0.30Weighted average common shares outstanding, basic

5,305,2965,260,4625,289,0665,248,011Weighted average common shares outstanding, diluted

5,316,6575,266,4615,304,1295,255,354 Psychemedics CorporationBalance Sheets(UNAUDITED)June 30,December 31,20132012ASSETS Current Assets:Cash and cash equivalents

$2,729,175$3,065,785Accounts receivable, net of allowance for doubtful accountsof $144,088 in 2013 and $121,583 in 2012

5,190,2994,620,768Prepaid expenses and other current assets

978,624823,274Income tax receivable

--854,212Deferred tax assets304,124209,877Total Current Assets

9,202,2229,573,916Fixed Assets, net of accumulated amortization and depreciationof $4,804,135 in 2013 and $4,395,605 in 2012

4,489,3084,201,409Other assets

436,730345,293Total Assets

$ 14,128,260$  14,120,618LIABILITIES AND SHAREHOLDERS' EQUITYCurrent Liabilities:Accounts payable

$577,192$669,789Accrued expenses

1,081,7641,413,541Total Current Liabilities

1,658,9562,083,330Deferred tax liabilities, long-term

814,619814,619Total Liabilities

2,473,5752,897,949Shareholders' Equity:Preferred-stock, $0.005 par value, 872,521 shares authorized,

----no shares issued or outstandingCommon stock, $0.005 par value; 50,000,000 shares authorized5,979,508 shares issued in 2013 and 5,940,558 shares issued in 2012 

29,89829,703Additional paid-in capital

28,592,45328,460,764Accumulated deficit

(6,885,877)(7,186,009)Less - Treasury stock, at cost, 668,130 shares in 2013 and 2012

(10,081,789)(10,081,789)Total Shareholders' Equity

11,654,68511,222,669Total Liabilities and Shareholders' Equity


SOURCE Psychemedics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Psychemedics Corporation Announces 3rd Quarter Earnings
2. Psychemedics Corporation Announces Record Revenues For 2012; Declares 66th Consecutive Quarterly Dividend
3. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
4. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
5. Richard Wolf Medical Instruments Corporation: 40 Years of Innovation
6. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
7. Luminex Corporation Reports First Quarter 2012 Results
8. ShangPharma Corporation Files 2011 Annual Report on Form 20-F
9. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
10. Without Environmental Hygiene, Hand Hygiene Programs Fall Short in Reducing HAIs in Hospital Settings, Says UMF Corporation
11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Post Your Comments:
(Date:11/25/2015)... 2015 Research and Markets ( ) ... - Global Forecast to 2020" report to their ... for 37.21% of the total market share in 2014. ... region is projected to growth at the highest CAGR ... primarily to the fast growing water, industrial gas treatment, ...
(Date:11/24/2015)... 25, 2015 WuXi PharmaTech (Cayman) Inc. ("WuXi" ... open-access R&D capability and technology platform company serving the ... China and the ... extraordinary general meeting of shareholders held today, the Company,s ... and approve the previously announced agreement and plan of ...
(Date:11/24/2015)... N.C. , Nov. 24, 2015  In the ... projects in an effort to quickly uncover new insights, ... --> --> However, ... a market research project and ensure that all rules ... and industry standards. Another major barrier to efficiently launching ...
Breaking Medicine Technology:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... has focused on providing comprehensive solutions involving adult stem cell therapies to patients ... officially deemed the “Regenestem” name as a Registered Trademark (RTM). , Organizations are ...
(Date:11/25/2015)... ... 25, 2015 , ... Bunion Bootie , the newest ... of the early holiday shopping season. Starting Wednesday November 25th, Bunion Booties are ... Friday promotional pricing is in addition to any automatic discounts applied when buying ...
(Date:11/24/2015)... ... November 24, 2015 , ... Eric C. Seidel, ... many benefits of the revolutionary BIOLASE WaterLase iPlus 2.0™ system. This advanced laser ... used by a dentist in Gettysburg, PA . From routine visits to ...
(Date:11/24/2015)... ... , ... New patients who wish to seek treatment for missing teeth can ... her Mississauga, ON practice. Dr. Williams has been providing dental service for over 34 ... Missing teeth can lead to a variety of complications if they are not replaced ...
(Date:11/24/2015)... ... ... Charitable giving is at its peak during the holidays. In fact, ... the year totalling over $358 billion in 2014. With more than 1.5 million ... individuals who want to “give back” during the holidays. , “With so many charities ...
Breaking Medicine News(10 mins):